Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.74 |
| ▸ | ABL1 | P00519 | 18/20 | 0.74 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.74 |
| ▸ | EGFR | P00533 | 17/20 | 0.74 |
| ▸ | HCK | P08631 | 17/20 | 0.74 |
| ▸ | KDR | P35968 | 17/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.74 |
| ▸ | MTOR | P42345 | 17/20 | 0.74 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.74 |
| ▸ | EPHB4 | P54760 | 17/20 | 0.74 |
| ▸ | PRKDC | P78527 | 17/20 | 0.74 |
| ▸ | PI4KB | Q9UBF8 | 12/20 | 0.74 |
| ▸ | PIK3CB | P42338 | 15/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18874138 | 0.86 | PIK3CD (0.55) | SRCABL1PIK3CDEGFRHCK | |
| SCHEMBL2432675 | 0.85 | SRC (1.00) | SRCABL1PIK3CDEGFRHCK | |
| SCHEMBL2437472 | 0.85 | SRC (1.00) | SRCABL1PIK3CDEGFRHCK | |
| SCHEMBL2464877 | 0.80 | PIK3CD (1.00) | SRCABL1PIK3CDEGFRHCK | |
| SCHEMBL18868086 | 0.78 | ABL1 (0.74) | SRCABL1PIK3CDEGFRHCK | |
| SCHEMBL17401183 | 0.77 | PIK3CD (0.54) | SRCABL1PIK3CDEGFRHCK | |
| SCHEMBL17331503 | 0.77 | PIK3CD (0.55) | SRCABL1PIK3CDEGFRHCK | |
| SCHEMBL17401169 | 0.77 | PIK3CD (0.54) | SRCABL1PIK3CDEGFRHCK | |
| SCHEMBL17397227 | 0.77 | PIK3CD (0.54) | SRCABL1PIK3CDEGFRHCK | |
| SCHEMBL3614988 | 0.77 | ABL1 (1.00) | SRCABL1PIK3CDEGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R1, PIK3R4 | SRC 106/4885ABL1 53/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.